Related Experiment Videos
[Immunocorrective therapy of pyelonephritis in children]
Urologiia I Nefrologiia
|September 1, 1989
Summary
Tactivin, an immunomodulatory polypeptide drug, effectively treated pyelonephritis in children, improving clinical and lab markers. This immunological treatment demonstrated significant efficacy with no observed side effects.
Area of Science:
- Immunology
- Pediatric Nephrology
Context:
- Pyelonephritis is a significant kidney infection in children.
- Immunological treatments offer potential therapeutic avenues.
Purpose:
- To evaluate the efficacy and safety of tactivin, a polypeptide drug, in treating acute and chronic pyelonephritis in children.
Summary:
- A study involving 40 children with pyelonephritis showed that 82.5% experienced clinical and laboratory improvements with tactivin treatment.
- Improvements included reduced proteinuria, normalized urinary sedimentation, and decreased bacteriuria, indicating enhanced resistance to infection.
- While 15% had persistent leukocyturia, disease progression was still hindered, and no adverse effects were reported.
Impact:
- Tactivin administration stimulated humoral immune response and complement system activation.
- The drug enhanced T-lymphocyte competence, contributing to favorable disease pathogenesis in pediatric pyelonephritis.
- This study highlights tactivin as a potentially valuable agent in the combined treatment of pediatric kidney infections.